FAS and metabolic dysfunction-associated steatotic liver disease: Therefore, the inhibition of de novo lipogenesis through downregulating the expressions of ACC and FAS might be at least one of the mechanisms for berberine to alleviate NAFLD, which is distinguished from that of bicyclol, and finally co-contribute to the enhancement of therapeutic effect against NAFLD when combined with berberine and bicyclol.